More recently, Kadiyala et al. developed a genetically engineered mouse model of glioma expressing IDH1R132H and loss of ATRX and TP53 to better understand the role played by 2-HG in influencing the glioma immune microenvironment [35] (Table 1). The gene discussed is TP53; the disease is central nervous system cancer.